National Patterns of Care Study October 2009

Slides:

Advertisements

Similar presentations

Hematopathology Lab December 12, Case 1 . Normal Peripheral Blood Smear.

Advertisements

Dr Kavita Raj Consultant Haematologist Guys and St Thomas’ Hospital.

The National CML Society 2012 CML UPDATE “What’s New? What’s Coming?” Luke Akard MD Co-Director Indiana Blood and Marrow Transplantation Program.

Hematology RBC/WBC Case Studies

A Hematology Case Study about Leukemia by Sarah Wycoff

Chronic leukaemias Chronic myelogenous leukaemia Chronic myelogenous leukaemia Chronic lymphocytic leukaemia Chronic lymphocytic leukaemia.

Identification and Diagnosis of the Acute Leukemias

This lecture was conducted during the Nephrology Unit Grand Ground by Nephrology Registrar under Nephrology Division, Department of Medicine in King Saud.

Rakesh Biswas MD Professor, Medicine, People's College of Medical Sciences, Bhopal, India Lecture first conceived and delivered to medicine undergrads.

NYU Medicine Grand Rounds Clinical Vignette Maryann Kwa, MD PGY-2 January 12, 2011 U NITED S TATES D EPARTMENT OF V ETERANS A FFAIRS.

History 2: 70 year old female

The acute Leukemias are clonal hematopoietic malignant disease that arise from the malignant T r a n s f o r m a t i o n of an early Hematopoietic stem.

Copyright © 2011, Research To Practice, All rights reserved. National Patterns of Care Study in Breast Cancer Launched October US-based community.

Copyright © 2009 Research To Practice. All rights reserved. National Patterns of Care Study October Randomly Selected US-based Medical Oncologists.

MOLECULAR GENETICS and LEUKEMIA Clive S. Zent M.D. Division of Hematology/Oncology.

ICCS e-Newsletter CSI Fall 2010 David D. Grier, M.D. Department of Pathology. Wake Forest University.

Copyright © 2011 Research To Practice. All rights reserved. What Clinicians Want to Know A Live CME Event Addressing the Most Common Questions and Controversies.

Treatment of CML. Goal of Therapy Complete molecular remission and cure – Achieve prolonged, durable, nonneoplastic, nonclonal hematopoiesis, – Eradication.

Single-Agent Lenalidomide Induces Complete Remission of Acute Myeloid Leukemia in Patients with Isolated Trisomy 13 Fehniger TA et al. Blood 2009;113(5):

TREATMENT. Phases of treatment Induction chemotherapy Postremission therapy *Initial goal: quickly induce CR *Therapy depends on patient age.

Acute Leukemia Kristine Krafts, M.D..

1 CASE REPORT hematology Monika Csóka MD, PhD year old boy no abnormalities in previous anamnesis 2 weeks before viral infection (fever, coughing)

Treatment. Phases of treatment Induction chemotherapy Postremission therapy *Initial goal: quickly induce CR *Therapy depends on patient age.

1 NDA Nelarabine. 2 Proposed Indication Nelarabine is indicated for the treatment of patients with T-cell acute lymphoblastic leukemia (ALL) and.

Case report Sudden blastic transformation in patient with chronic myeloid leukemia treated with imatinib mesylate Mehrdad Payandeh,MD Hematology, Medical.

Daunorubicin VS Mitoxantrone VS Idarubicin As Induction and Consolidation Chemotherapy for Adults with Acute Myeloid Leukemia : The EORTC and GIMEMA Groups.

Case 251: Clinical Information Raymond E Felgar, MD, PhD University of Pittsburgh, Pittsburgh, PA 45-year-old man with recent history of shingles, night.

Acute lymphoblastic leukemia in children

Case 255 Elizabeth Courville, MD Robert Hasserjian, MD Massachusetts General Hospital Society for Hematopathology/European Association for Haematopathology.

AML Clinical Presentation. Clinical Presentation: Symptoms Fatigue (50%) Anorexia and weight loss Fever with or without an identifiable infection (10%)

Case 398 Submitting Author: Hutchison, Robert E, MD Institution: SUNY Upstate Medical University Additional authors: Constance K. Stein, Ph.D., Theresa.

Society for Hematopathology/ European Association for Haematopathology Case 211 Rachel Ochs, MD Adam Bagg, MD Hospital of the University of Pennsylvania.

Case 316 Ryan Johnson, MD; Athena Cherry, PhD; Dita Gratzinger, MD, PhD Stanford University Medical Center SH-EAHP October 24, 2013.

BLOOD AND BODY DEFENCE Dr. Amel Eassawi Dr. Abdelrahman Mustafa 1.

CASE 411 Jose Gonzalez-Berjon, MD & Tariq Muzzafar, MD UT M.D. Anderson Cancer Center.

Patient history 70 year-old male with macrocytic anemia for 10 years, became transfusion dependent. Splenectomy for refractory anemia: 670gm B12, folate,

Acute Leukemia Kristine Krafts, M.D..

Adam J. Wood, D.O. Rhett P. Ketterling, M.D. April E. Chiu, M.D.

CASE SUBMISSION 2016 EAHP BM Workshop

Iron deficiency anemia. (Peripheral blood, 50 ×

REVIEW AML RECURRENCE R3 조경민.

Hairy cell leukemia. (Bone marrow core biopsy, 50 ×

18th Meeting of the European Association for Hematopathology

Hairy cell leukemia. (Bone marrow core biopsy, 50 ×

CHRONIC MYELOID LEUKEMIA (CML)

Resistance in the land of molecular cancer therapeutics

by Christopher Dittus, and Dana Semmel

University of Vermont Medical Center

by Ambra Paolini, and Goretta Bonacorsi

Leukemia Case 1.

Kantarjian H et al. Cancer 2009;[Epub ahead of print].

Case Study ….

by Vishal Bhatnagar, and Ashkan Emadi

Fenaux P et al. Lancet Oncol 2009;10(3):

Case:2 leukemia دينا نعمان جرادة جيهان ايمن مقاط.

A young patient with multiple myeloma

LEUKEMIA CASE STUDY 2.

Diagnostic Hematology

by Toru Takahashi, and Masafumi Matsuguma

Leukemia case (18).

Case study A 36-year-old woman presented with a two-month history of increasing fatigue and abdominal fullness with accompanying loss of appetite. There.

A Case Report Ahmad Adel A..

Ospedale S. Eugenio – Cattedra di Ematologia Università Tor Vergata

Case study 14 Hadeel , Huda , Abeer.

A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia by Lili Aslostovar, Allison L. Boyd, Mohammed.

Langerhance Cell Histiocytosis (LCH) 5 Years After B-cell Acute Lymphoblastic Leukemia in a 11 year-old boy Professor. Ansari Professor of pediatric hematology.

Treatment versus Transplant for Challenging Hematologic Disorders

Presentation transcript:

National Patterns of Care Study October 2009 100 Randomly Selected US-based Medical Oncologists in Practice

Approximately what percentage of your practice involves treatment of solid tumors versus hematologic issues? Source: National Patterns of Care study of 75 randomly selected US-based medical oncologists in practice, October 2008 Copyright © 2009 Research To Practice. All rights reserved.

In the past year, how many patients have you seen with… Copyright © 2009 Research To Practice. All rights reserved.

Do you generally directly manage patients with AML or refer them to a tertiary center? Copyright © 2009 Research To Practice. All rights reserved.

What is this patient’s diagnosis? CASE 1 68-year-old woman Hgb 9.6 g/dL, WBC 2.0 x 103/mm3, Platelets 160,000/µL 32% blasts by flow cytometry Specimen insufficient for cytogenetics What is this patient’s diagnosis? Copyright © 2009 Research To Practice. All rights reserved.

CASE 1 Which treatment*, if any, would you recommend at this time? *Treatment selection made from survey answer choices Copyright © 2009 Research To Practice. All rights reserved.

CASE 1 If the patient were treated with azacitidine, which initial dose and schedule would you recommend? Copyright © 2009 Research To Practice. All rights reserved.

CASE 2 59-year-old woman Hgb 8.5 g/dL, WBC 1.7 x 103/mm3, Platelets 30,000/µL 60% blasts on bone marrow biopsy CD33 and CD34 positivity; normal chromosome analysis

CASE 2 How would you respond if this patient asked you what her chance of cure was with conventional treatment? PERCENT Copyright © 2009 Research To Practice. All rights reserved.

CASE 2 Which additional molecular studies, if any, would you recommend for a patient with AML and normal cytogenetics? Copyright © 2009 Research To Practice. All rights reserved.

CASE 2 Which treatment*, if any, would you recommend at this time? *Treatment selection made from survey answer choices Copyright © 2009 Research To Practice. All rights reserved.

CASE 2 The patient would like to take an herbal supplement in addition to conventional treatment and asks your opinion. How would you respond? Copyright © 2009 Research To Practice. All rights reserved.

CASE 2 Assume this patient received standard induction with 7 + 3 cytarabine and idarubicin and achieved remission. Which course of therapy* would you recommend at this point? *Course of therapy selection made from survey answer choices Copyright © 2009 Research To Practice. All rights reserved.

CASE 3 Generalized bruising and fever (100.4° F) 81-year-old woman Generalized bruising and fever (100.4° F) CBC: Hgb 8.6 g/dL with MCV 112 fl, WBC 4.8 x 103/mm3 Platelets 19,000/L 90% myeloblasts in the peripheral blood

CASE 3 Would you perform a confirmatory bone marrow biopsy on this patient? Copyright © 2009 Research To Practice. All rights reserved.

CASE 3 Which treatment*, if any, would you recommend? *Treatment selection made from survey answer choices Copyright © 2009 Research To Practice. All rights reserved.